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Clinical practice guidelines recommend blockers of the
renin-angiotensin system alone or in combination with other
agents to reduce blood pressure and albuminuria in patients
with type 2 diabetes. Dihydropyridine calcium channel
blockers, however, may lower blood pressure but not
albuminuria in these patients. Here we tested the hypothesis
that combining an ACE inhibitor with either a thiazide
diuretic or a calcium channel blocker will cause similar
reductions in blood pressure and albuminuria in
hypertensive type 2 diabetics. We conducted a double blind
randomized controlled trial on 332 hypertensive, albuminuric
type 2 diabetic patients treated with benazepril with either
amlodipine or hydrochlorothiazide for 1 year. The trial
employed a non-inferiority design. Both combinations
significantly reduced the urinary albumin to creatinine ratio
and sitting blood pressure of the entire cohort. The
percentage of patients progressing to overt proteinuria was
similar for both groups. When we examined patients who
had only microalbuminuria and hypertension we found that
a larger percentage of the diuretic and ACE inhibitor
normalized their albuminuria. We conclude that initial
treatment using benzaepril with a diuretic resulted in a
greater reduction in albuminuria compared to the group of
ACE inhibitor and calcium channel blocker. In contrast, blood
pressure reduction, particularly the diastolic component,
favored the combination with amilodipine. The dissociation
between reductions in blood pressure and albuminuria may
be related to factors other than blood pressure.
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A coexistent diagnosis of hypertension and diabetes mellitus
increases the risk for adverse cardiovascular and renal
outcomes. This increased risk for adverse outcomes extends
to a diastolic blood pressure (DBP) as low as 83 mm Hg and a
systolic BP (SBP) as low as 127 mm Hg.1,2 Microalbuminuria,
an early clinical marker of vascular dysfunction in the kidney, is
a strong prognostic indicator of both mortality and cardiovas-
cular disease in patients with hypertension and diabetes.3,4 In
the Heart Outcomes Prevention Evaluation (HOPE), patients
with microalbuminuria at baseline had an increased risk of the
combined end point of myocardial infarction, stroke, or
cardiovascular death irrespective of their diabetes status.5
Important therapeutic strategies to slow the decline in
kidney function includes both aggressive BP reduction to a
goal of o130/80 mm Hg in patients with hypertension and
diabetes,1,4,6 as well as a greater than 30% reduction in
albuminuria.7 More than 75% of these patients will require a
combination of a renin–angiotensin system blocker with
either a diuretic or calcium antagonist to achieve these
guideline goals.1,2,8 The Gauging Albuminuria Reduction
With Lotrel in Diabetic Patients With Hypertension
(GUARD) trial tested initial combination therapy of either
a dihydropyridine calcium channel blockers or thiazide
diuretic combined with the same angiotensin-converting
enzyme (ACE) inhibitor in the reduction of blood pressure
(BP) and albuminuria in patients with hypertension and type
II diabetes. Changes in the urinary albumin excretion as
assessed by a spot albumin-to-creatinine (Ualb:Cr) ratio after
52 weeks of treatment were compared in patients with
hypertension, type II diabetes, and albuminuria randomized
to a fixed-dose ACE inhibitor/calcium channel blockers
(CCB) combination (benazepril/amlodipine; BþA) or fixed-
dose ACE inhibitor/diuretic combination (benazepril/hydro-
chlorothiazide; BþHCTZ). The rationale and design of the
study are described elsewhere.9
RESULTS
Patients
Of the 332 patients (166 in each group) randomized to
treatment, 65 (27 patients, BþA; 38, BþHCTZ) patients
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prematurely discontinued from the study primarily due to
adverse events (AEs), being lost to follow-up, unsatisfactory
therapeutic effect, or withdrawal of consent (Figure 1).
Among the patients who discontinued, 13 patients in the
BþA arm and 15 patients in the BþHCTZ arm had one
post-baseline assessment conducted and were included in the
intent-to-treat population. Thus, the intent-to-treat popula-
tion included 153 patients in the amlodipine/benazepril and
151 patients in the BþHCTZ treatment groups. The safety
population included all 332 randomized patients (166 per
treatment group).
The demographic and clinical characteristics of the two
treatment groups were similar (Table 1). The median baseline
laboratory parameters for efficacy variables were not
significantly different between treatment groups (Table 2),
except for a lower B-type natriuretic peptide levels (BNP) in
the BþA group (17.0 vs 22.0 pg ml1; P¼ 0.0369) (Table 2).
All patients in both treatment groups underwent the placebo
run-in phase and were administered a dose of BþA 20/5 mg
or BþHCTZ 20/12.5 mg, respectively, at the time of
Randomized patients
(N=332)
Benazepril/HCTZ
(N=166)
Benazepril/amlodipine
(N=166)
Discontinued
(N=27) Discontinued (N=38)
Intent to treat
(N=153)
Intent to treat
(N=151)
Reasons for discontinuation
• Death (1)
• Adverse events (9)
• Protocol violation (2)
• Withdrawal of consent (4)
• Lost to follow-up (9)
• Other (2)
Reasons for discontinuation
• Death (2)
• Abnormal lab values (1)
• Adverse events (18)
Lack of therapeutic efficacy (5)
Protocol violation (3)
•
•
•
Withdrawal of consent (6)
Lost to follow-up (3)
•
•
Other (2)
Figure 1 | Patient disposition.
Table 1 | Baseline demographic and clinical characteristics of
all patients randomized to treatment (safety population)
Characteristic
Benazepril/amlodipine
(n=166)
Benazepril/HCTZ
(n=166)
Age (years), mean
(±s.d.)
57.7 (±10.9) 57.7 (±10.9)
Age group, n (%)
o65 years 121 (72.9) 118 (71.1)
X65 years 45 (27.1) 48 (28.9)
Gender, n (%)
Male 109 (65.7) 108 (65.1)
Female 57 (34.3) 58 (34.9)
Race, n (%)
White 107 (64.5) 93 (56.0)
Black 36 (21.7) 51 (30.7)
Asian 4 (2.4) 1 (0.6)
Other 19 (11.4) 21 (12.7)
Mean sitting BP, mm Hg±s.d.
Systolic 150±13.3 151±13.1
Diastolic 88.4±9.10 87.2±9.74
Mean BMI (kg m2) 34.8±7.84 35.5±8.20
BMI, body mass index; BP, blood pressure; HCTZ, hydrochlorothiazide.
Table 2 | Median baseline laboratory values for the intent-to-
treat population
B+A (n=153) B+HCTZ (n=151) P-value
U alb:Cr ratio (mg g1)
Median 56.9 64.2 0.24
Range 10.3–570 15.9–693
n 148 146
Estimated GFR (ml min1)
Median 91.6 89.6 0.80
Range 47.1–180 45.2–175
n 153 150
Insulin resistance (HOMA-IR)
Median 5.20 5.60 0.68
Range 0.50–43.0 0.50–104
n 146 140
Albuminuria (g per 100 ml)
Median 4.20 4.20 0.65
Range 2.50–5.60 3.00–4.80
n 153 150
BNP (pg ml1)
Median 17.0 22.0 0.04
Range 4.99–336 4.99–383
n 148 142
hs-CRP (mg per 100 ml)
Median 0.32 0.32 0.49
Range 0.00–5.28 0.02–15.8
n 148 148
BNP, B-type natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein; GFR,
glomerular filtration rate; HCTZ, hydrochlorothiazide; HOMA-IR, homeostasis model
assessment of insulin resistance; Ualb:Cr, urinary albumin-to-creatinine.
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randomization. Approximately 85% in both treatment
groups required titration to the next dose level (BþA 40/
5 mg, n¼ 147; BþHCTZ 40/12.5 mg, n¼ 141), and approxi-
mately 70% of these participants in both treatment groups
required titration to maximal doses (BþA 40/10 mg,
n¼ 124; BþHCTZ 40/25 mg, n¼ 114). Concomitant anti-
hypertensive rescue medication use was similar between the
two treatment groups. The most frequent concomitant
antihypertensive rescue medications used in both arms were
selective b-blocking agents (27.7% in each group), and the
most frequently used b-blocking agent was metoprolol
succinate (18.7% in the BþA group and 16.3% in the
BþHCTZ group). A slightly higher percentage of subjects in
the BþA group than that in the BþHCTZ group used the
following concomitant medications: biguanides (57.2 vs
42.8%, respectively); macrolides (13.3 vs 6.0%, respectively);
and adrenergics and other drugs for obstructive airway
disease (11.4% vs 3.0%, respectively).
Primary outcome
Both BþA and BþHCTZ significantly decreased the
median percent change in the Ualb:Cr ratio from baseline
to end of the study for the entire cohort. There was a smaller
percent change from baseline in the BþA group (median
percent change: 40.5%; range: 98.3 to 880%) than that in
the BþHCTZ group (median percent change: 72.1%;
range: 98.4 to 590%) (Po0.0001) (Figure 2). Using the
ANCOVA (analysis of covariance) model and after adjusting
for baseline BNP and reduction in BP as covariates, similar
results were observed, with smaller reductions in the Ualb:Cr
ratio from baseline in the BþA group (median change:
17.4 mg g1; range: 281 to 365 mg g1) than that in the
BþHCTZ group (median change: 43.0mg g1; range:
611 to 378 mg g1) (P¼ 0.0003).
Reductions from baseline in sitting SBP and DBP were
significant in both treatment groups (Po0.0001) (Figure 3).
The mean reduction in both SBP and DBP was greater in the
BþA arm than in the BþHCTZ arm; however, significance
in favor of BþA was observed only for DBP (SBP: 20.5 vs
18.8, P¼ 0.19; DBP: 13.1 vs 9.97, P¼ 0.02; Figure 3).
A greater proportion of patients who had microalbumi-
nuria at baseline and treated with BþHCTZ compared with
BþA attained normalization of the Ualb:Cr ratio, defined as
o30 mg g1 (69.2 vs 47.8%; P¼ 0.0004) (Figure 4).
Subgroup analyses
Subgroup analyses revealed small but significant differences
between groups in both the absolute and percent change
from baseline in the Ualb:Cr ratio for age (Po0.0001), high
and low stratum (P¼ 0.0012 and Po0.001, respectively), and
SBP (Po0.05). There were no differences between treatment
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Figure 2 | Median percent change in the urinary albumin-to-
creatinine (Ualb:Cr) ratio from baseline at week 52 (LOCF) for
the entire intent-to-treat cohort. Note: Baseline data was
available for 148 patients in the benazepril/amlodipine group and
146 patients in the benazepril/HCTZ group. At the end of the
study (week 52, last observation carried forward; LOCF) data were
available for only 145 patients in each group. HCTZ,
hydrochlorothiazide.
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Figure 3 | Mean change in sitting systolic and diastolic blood
pressure from baseline at Week 52 by treatment group. SBP,
systolic blood pressure; DBP, diastolic blood pressure.
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Figure 4 | Proportion of patients with microalbuminuria only
who attained normalization of the urinary albumin-to-
creatinine (Ualb:Cr) ratio (o30 mg g1) by the end of the
study (intent-to-treat population). Baseline data were available
for 148 patients in the benazepril/amlodpine group and 146
patients in the benazepril/HCTZ group. The data shown exclude
patients who had a baseline Ualb:Cr ratio of o30 mg g1
(benazepril/amlodipine: 33 patients and benazepril/HCTZ 13
patients).
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groups in the primary efficacy variable in patients X65 years
(P¼ 0.3828) or in patients with a SBP between 120 and
129 mm Hg at end of the study (P¼ 0.0715). In all SBP
subgroups, the median percent decrease from baseline in the
Ualb:Cr ratio was significantly smaller in the BþA treatment
group than that in the BþHCTZ group (Po0.05).
We also conducted an exploratory analysis in patients with
baseline Ualb:Cr ratio between 30 and 300 mg g1 for
primary efficacy variable. In this analysis, differences between
the two treatment groups for median percent change from
baseline in the Ualb:Cr ratio were similar to those observed in
the entire study population with smaller percent change
in the BþA group (46.3%, range: 98.3 to 265) than that
in the BþHCTZ group (73.0%, range: 98.4 to 590%),
Po0.001). As observed with the entire study population, a
greater proportion of patients treated with BþHCTZ than
with BþA attained normalization of the Ualb:Cr ratio,
defined as o30 mg g1 (76.5 vs 52.4%; P¼ 0.0001).
Rates of progression to overt diabetic nephropathy, that is,
4300 mg g1 creatinine, by end of the study were similar
between the two groups (4.6 vs 4.0%; P¼ 0.7901). In a
logistic regression analysis, there were no associations of
treatment, age, race, baseline SBP, baseline DBP, baseline
HbA1c (hemoglobin A1c), and baseline albuminuria with the
development of overt diabetic nephropathy by week 52
(P40.05 for all variables).
Secondary outcome
No significant differences were found for other secondary
laboratory efficacy measures at end of the study, including
changes in HOMA-IR (homeostasis model assessment of
insulin resistance) (P¼ 0.30), albuminuria (P¼ 0.83), BNP
(P¼ 0.83), or high-sensitivity C-reactive protein (hs-CRP;
P¼ 0.33). In contrast, the mean decrease in the estimated
glomerular filtration rate (eGFR) over the 52-week period
was less in the BþA group than in the BþHCTZ
group (2.03±14.2 vs 13.64±16.1 ml min1; Po0.0001)
(Figure 5). Additionally, we tested for an interaction between
baseline BNP differences and change in albumin:creatinine;
however, a significant interaction was not present (P¼ 0.99).
Side effects
Overall, both study drugs were well tolerated. AEs occurring
in X5% of patients in either treatment group regardless of
relationship to study drug are summarized in Table 3. The
most frequently reported AEs of suspected relationship to
study drug occurred in the general disorders and adminis-
tration site conditions system organ class (11.4 and 3.6% in
the BþA and BþHCTZ groups, respectively) and included
peripheral edema (7.8 vs 2.4%, respectively), fatigue (1.2% in
each group), pitting edema (1.2 vs 0%, respectively), face
edema (0.6 vs 0.0%, respectively), and thirst (0.6 vs 0.0%,
respectively). More patients in the BþHCTZ group (18;
10.8%) than in the BþA group (9; 5.4%) discontinued study
drug treatment due to AEs. The most common reasons for
discontinuation were cardiac disorders (2; 1.8%), peripheral
edema (1; 0.6%), infections (2;1.2%), benign neoplasms
(1; 0.6%), thoracic events (2; 1.2%), and hypotension
(1; 0.6%) in the BþA group and cardiac disorders (3;
1.8%), peripheral edema (1; 0.6%), fatigue (1; 0.6%),
asthenia (1; 0.6%), metabolic disorders (2; 1.2%), nervous
system disorders (4; 2.4%), vascular disorders (2; 1.2%), and
thoracic disorders (4; 2.4%) in the BþHCTZ group. The
three deaths that occurred (one in the BþA group and two
in the BþHCTZ group) were not considered to be related to
study drug treatment.
DISCUSSION
Clinical practice guidelines uniformly recommend that initial
treatment of hypertension in those with diabetes or kidney
disease include either an ACE inhibitor or an angiotensin
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Figure 5 | Mean change in estimated glomerular filtration rate
(eGFR) from baseline to end of study. Baseline data were
available for 153 patients in the benazepril/amlodipine group and
150 patients in the benazepril/HCTZ group. End of the study
(week 52, LOCF) data were available for all patients with a baseline
measurement.
Table 3 | Summary of AEs occurring in X5% of patients in
either treatment group (safety population)
Number (%) of patients
AE
Benazepril/amlodipine
(n=166)
Benazepril/HCTZ
(n=166)
Peripheral edema 29 (17.5) 12 (7.2)
Cough 23 (13.9) 17 (10.2)
Upper respiratory tract
infection
16 (9.6) 16 (9.6)
Dizziness 15 (9.0) 11 (6.6)
Headache 14 (8.4) 16 (9.6)
Bronchitis 14 (8.4) 12 (7.2)
Diarrhea 14 (8.4) 11 (6.6)
Arthralgia 14 (8.4) 13 (7.8)
Fatigue 13 (7.8) 13 (7.8)
Back pain 13 (7.8) 10 (6.0)
Muscle spasms 11 (6.6) 7 (4.2)
Nasopharyngitis 10 (6.0) 13 (7.8)
Urinary tract infection 10 (6.0) 8 (4.8)
Nausea 7 (4.2) 11 (6.6)
Pain in extremity 7 (4.2) 11 (6.6)
AE, adverse event; HCTZ, hydrochlorothiazide.
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receptor blocker (ARB).1,4,8 However, such guidelines do not
provide consistent recommendations for a second drug class
if needed to achieve BP goal ofo130/80 mm Hg. Large-scale,
randomized, multicenter trials of both ACE inhibitors and
ARBs in patients with kidney disease (similar to our cohort)
have demonstrated reduction in microalbuminuria.10,11
However, in these trials, the ACE inhibitor and ARBs were
used as monotherapy. Both CCB and diuretics when added to
either an ACE or an ARB further reduce BP; however, the
impact on albuminuria was previously unknown. In the
Reduction of End points in NIDDM (non-insulin-dependent
diabetes mellitus) With the Angiotensin II Antagonist
Losartan (RENAAL) Study,12 the use of amlodipine as a
concurrent therapy to losartan yielded a similar outcome as
seen for the losartan cohort with no difference in albumi-
nuria reduction compared with the participants who did not
use amlodipine. The principal new finding in our study was
that in hypertensive patients with diabetes and microalbu-
minuria, both fixed-dose combinations of the ACE inhibitor
benazepril, with CCB, amlodipine, or with the diuretic
hydrochlorothiazide reduce the Ualb:Cr ratio. We also found
that the reduction in the Ualb:Cr ratio was significantly
greater with BþHCTZ combination than with BþA
combination, both in the entire population and in patients
with baseline Ualb:Cr ratio between 30 and 300 mg g1.
However, the mean rate of decline in GFR was slower in those
randomized to the BþA than those randomized to the
BþHCTZ combination that may have affected the changes
in microalbuminuria. Thus, our study findings did not
support our hypothesis of no difference in albuminuria given
similar levels of BP reduction with either ACE/CCB or ACE/
diuretic combination.
The reasons for the greater reduction in Ualb:Cr in the
BþHCTZ group cannot be determined from our study.
Possible explanations include greater reductions in eGFR in
the diuretic group as well as differences in preexisting volume
status. Although there were no interactions between BNP and
albuminuria in our study, it should be noted that the plasma
levels of BNP are increased in people consuming a high level of
sodium.13 High sodium intake generally blunts the anti-
proteinuric effects of RAS blockers; however, the use of
thiazide diuretics overcomes this blunting effect.14–16 Unfortu-
nately, in our study, we could not definitely ascertain whether
the difference in volume reflected by baseline BNP contributed
to the differences in albuminuria, as we did not monitor
urinary sodium levels. Thus, the greater decrease in Ualb:Cr in
the BþHCTZ group should be interpreted with caution.
There is limited information available on the influence of
diuretics on urinary albumin excretion.17,18 Whereas some
investigators have reported no effect of thiazide diuretics on
albumin excretion,19 others have reported an increase in
microalbuminuria with diuretics.20 However, studies have
reported that the addition of hydrochlorothiazide can
overcome the blunting of the therapeutic efficacy of ACE
inhibition on proteinuria caused by high sodium intake.14
Indeed, increased dietary salt intake is well known to offset
the antiproteinuric effects of not only blockers of the
renin–angiotensin system but also that of CCBs.21 The
protocol used in our study did not mandate restriction on
salt intake. Future trials of fixed-dose combinations with
similar base components should consider protocol-driven
control of sodium intake and the measurement of urinary
sodium and blood BNP at baseline to isolate and handle this
potential source of confounding.
Another factor that may account for differences in
albuminuria is the relatively greater reduction in eGFR over
the study duration. Estimated GFR was calculated using the
modified MDRD (Modification of Diet in Renal Disease Study
Group) equation reported by Levey et al.22 and the modifica-
tion for Blacks when appropriate.23 The difference in eGFR
between the groups may have reflected additional volume
depletion, although side effect profiles were not different
between groups. Given that, the cohort had stage 1 and early
stage 2 nephropathy at baseline, a change in the eGFR seen in
the BþHCTZ group may have contributed to the further
reduction in albuminuria through decreased filtration.
In this study, there was no difference in change from
baseline in sitting SBP between the two treatment groups;
however, there was a significantly larger mean decrease from
baseline in sitting DBP in the BþA arm (Figure 2). This
difference in BP would normally be expected to yield a
greater antialbuminuric effect, but did not in this case. In this
study, 81 patients (53%) in the BþA arm and 78 patients
(52%) in the benazepril/hydrochorothiazide arm had a SBP
o130 mm Hg at end of the study. Although the number of
patients achieving target goal of DBP o80 mm Hg and
combined BP goal ofo130/80 mm Hg was not measured, the
greater reduction in the DBP achieved with the BþA arm
reflects better BP control.
Both BþA and BþHCTZ treatment were well tolerated
in our study. AEs generally were of mild or moderate severity
and were similar to those previously reported for ACE
inhibitors, CCB, and diuretics.
Albuminuria is recognized as an important predictor of
the risk of progression to ESRD and the risk of cardiovascular
events. However, this study does not allow us to extrapolate
the results obtained to make conclusions around the
potential impact on cardiovascular risk for the medications
studied. Notably, the ongoing ACCOMPLISH (Avoiding
Cardiovascular Events Through Combination Therapy in
Patients Living with Systolic Hypertension) study, a 12 000
patient mortality trial testing the same drug combinations in
GUARD, will shed further light on this issue in the context of
cardiovascular outcomes and kidney disease progression, as
the albumin:creatinine ratio and change in eGFR are being
assessed as pre-specified secondary end points.
In conclusion, both initial fixed-dose combinations
of benazepril/diuretic and BþA in hypertensive patients
with type II diabetic nephropathy resulted in significant
reductions in BP and urinary albuminuria with high rates of
normalization of the albumin:creatinine ratio and low
(o5%) rates of progression to overt proteinuria over 1 year.
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MATERIALS AND METHODS
Study design and patient population
GUARD was a 1-year, multicenter, randomized, double-blind parallel-
group study designed by the primary investigator in conjunction with
the sponsor, Novartis Pharmaceuticals Corporation, that assessed the
efficacy and tolerability of combination antihypertensive treatment
with either BþA or BþHCTZ to decrease the Ualb:Cr ratio. Eligible
subjects were men or women aged 21–85 years with type II diabetes
mellitus, albuminuria (defined as a Ualb:Cr ratio between 20 and
500 mg g1 confirmed in at least two of three consecutive morning
urine specimens), and hypertension (mean SBP, X130 mm Hg and
o180 mm Hg; mean DBP,X80 mm Hg ando110 mm Hg). Excluded
from the study were persons with kidney disease not caused by
diabetes and/or hypertension; confirmed or suspected renal artery
stenosis; a cardiovascular disease event (myocardial infarction, stroke,
transient ischemic attack, cardiovascular revascularization/angioplasty)
within the previous 6 months; evidence of heart failure or documented
left ventricular ejection fractiono40%; type I diabetes or uncontrolled
type II diabetes (HbA1c 49.5%); and a serum creatinine 41.5 mg per
100 ml for men and 41.3 mg per 100 ml for women. All patients gave
written informed consent before entry into the study.
Eligible participants who entered the study had their ACE
inhibitor, ARB, and aldosterone receptor blocker therapy withdrawn
after screening phase. This was followed by a 3-week placebo run-in
phase where all other antihypertensive agents were discontinued. At
the end of the placebo run-in phase, participants were randomized
to either BþA 20/5 mg or BþHCTZ 20/12.5 mg for 4 weeks to
achieve the target BP of o130/80 mm Hg. Those who had not
achieved the target BP were titrated at week 4 to BþA 40/5 mg or
BþHCTZ 40/12.5 mg for additional 4 weeks. Doses were again
titrated at week 8 to BþA 40/10 mg or BþHCTZ 40/25 mg in
patients who had not achieved the target BP (o130/80 mm Hg). At
week 12 and all subsequent visits, patients not meeting target BP
were titrated to the next dose level and all patients titrated to BþA
40/10 mg or BþHCTZ 40/25 mg received add-on antihypertensives,
including a-blockers, b-blockers, centrally acting antihypertensive
agents, and direct vasodilators, to achieve target BP. Prohibited as
add-on medications were other ACE inhibitors, ARBs, and
aldosterone receptor blockers.
Outcomes
The primary outcome was change in the Ualb:Cr ratio from
baseline to week 52. Secondary efficacy variables included the
proportion of patients who progressed to overt diabetic nephro-
pathy (as determined by a Ualb:Cr ratio of X300 mg g1 by week
52), the change from baseline to week 52 in eGFR using the
modified MDRD equation, the magnitude of albuminuria, the
biomarkers BNP and hs-CRP, and insulin sensitivity (HOMA-IR).
The safety and tolerability of combination treatment with BþA or
BþHCTZ were assessed by monitoring and recording all AEs as
well as monitoring clinical laboratory test results and findings from
physical assessments. All laboratory tests were performed at a
centralized lab.
Statistical methods
All statistical tests in this noninferiority trial were conducted against a
two-sided alternative hypothesis using a significance level of 0.05.9 For
testing the hypothesis of noninferiority of the CCB/ACE inhibitor
treatment regimen and the ACE inhibitor/diuretic treatment regimen,
a one-sided test was performed at the 2.5% level of significance (or
equivalently, a 97.5% one-sided confidence interval for the difference
will be used).9 Tests for the superiority of the CCB/ACE inhibitor
treatment regimen compared with the ACE inhibitor/diuretic
treatment regimen were based on the null hypothesis, and a two-
sided test will be performed at the 5% significance level.9
The sample size was determined based on 90% power, assuming
no difference in the change from baseline to week 52 in the
Ualb:Cr ratio between BþA and BþHCTZ treatment regimens.
The power calculations allowed for a dropout rate of 20% after
randomization. Thus, a sample size of 334 randomized subjects (167
per group) was necessary for this study. To assess differences
between the two groups for the primary efficacy variable, we
assumed a difference of 44 mg g1 in change in Ualb:Cr from
baseline between groups with a s.d. of 106 mg g1. This yielded a
two-sided significance level of 0.05, and an estimated number
of evaluable patients of 304 (152 per group). In retrospect, using
the final results in our assumptions, we find the power of the test is
95% (overpowered). Given the final results, only 246 (123 per
group) evaluable patients were required to detect 90% power
as planned.
Baseline demographic and clinical characteristics were summar-
ized by treatment group with appropriate descriptive statistics. w-
Test for categorical variables and one-way analysis of variance
(ANOVA) for continuous variables were used to test for homo-
geneity between the treatment groups at baseline.
Efficacy analyses were performed using the intent-to-treat
population, which included all randomized patients who received
at least one dose of study medication during the active treatment
phase and for whom there was at least one post-baseline
efficacy measurement. The Wilcoxon rank-sum test was used
for analyses of the primary efficacy variable, change from
baseline in the Ualb:Cr ratio, as the data were not normally
distributed. Because of the wide variability in the Ualb:Cr ratio,
the percent change from baseline in the Ualb:Cr ratio was identified
as being more clinically relevant statistic for analysis. In addition,
the data were not normally distributed and had a wide deviation
from the ‘mean.’ Hence, the ‘median’ was used to represent the
change from baseline and the difference from baseline was tested
using non-parametric analysis. The proportion of patients who
progressed to overt nephropathy was analyzed using the Cochran–-
Mantel–Haenszel w-test, adjusting by Ualb:Cr ratio strata (high:
211–500 mg g1; medium: 121–210 mg g1; low: 20–120 mg g1).
Additionally, we also used ANCOVA to analyze the treatment effect
on the Ualb:Cr ratio after adjusting for covariates of BP reduction
and BNP.
Safety analyses were performed using the safety population,
which included all randomized patients who received at least one
dose of study medication during the active treatment phase. The
incidence of AEs was summarized by primary organ system,
preferred term, severity, and relationship to study drugs. The
incidence of death, other serious AEs, and AEs leading to study
discontinuation were summarized separately.
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